BOSTON, April 16, 2024 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on April 11, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ – Research Report), Amylyx Pharmaceuticals Inc (AMLX – Research Report) and Rhythm Pharmaceuticals (RYTM – Research Report).
Johnson & Johnson (JNJ)
In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Hold rating on Johnson & Johnson, with a price target of $180.00. The company’s shares closed last Monday at $147.59, close to its 52-week low of $144.95.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Johnson & Johnson with a $178.82 average price target, implying a 20.5% upside from current levels. In a report issued on April 9, Morgan Stanley also maintained a Hold rating on the stock with a $168.00 price target.
See the top stocks recommended by analysts >>
Amylyx Pharmaceuticals Inc (AMLX)
Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Amylyx Pharmaceuticals Inc on April 11 and set a price target of $4.00. The company’s shares closed last Monday at $2.07, close to its 52-week low of $1.99.
According to TipRanks.com, Suvannavejh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Amylyx Pharmaceuticals Inc has an analyst consensus of Hold, with a price target consensus of $4.50, representing an 114.3% upside. In a report issued on March 27, Goldman Sachs also maintained a Hold rating on the stock with a $4.00 price target.
Rhythm Pharmaceuticals (RYTM)
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Rhythm Pharmaceuticals yesterday and set a price target of $49.00. The company’s shares closed last Monday at $40.09.
According to TipRanks.com, Ahmad is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rhythm Pharmaceuticals with a $56.43 average price target, which is a 39.5% upside from current levels. In a report issued on April 10, Needham also maintained a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on JNJ:
Analyst Joseph Stringer from Needham maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) and keeping the price target at $50.00. Joseph Stringer’s rating is based on a
Rhythm Pharmaceuticals has signed an investment agreement with current shareholders, led by Perceptive Advisors LLC and its Discovery Fund and a life-sciences focused institutional investor, for the sale of its
— Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 — — Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 —